Table 2.

Ventilator parameters and patient characteristics during the study protocol

ID	MVdays	Mode	PS	Cycloff	NAVAL	PEEP	FIO2	P/F	Sedation	RASS
1	6	PCV	13	30%	2.4	11	0.45	151	F	− 5
2	7	PCV	NA	NA	NA	16	0.35	183	None	− 2
3	3	PCV	NA	NA	NA	14	0.60	129	F, P	− 4
4	3	PCV	5	30%	0.2	15	0.30	376	F, P	− 4
5	1	PCV	8	25%	1.2	10	0.50	296	None	0
6	3	PCV	10	30%	0.6	10	0.45	136	F	− 4
7	4	PCV	6	40%	1.4	8	0.40	265	F, P	− 4
8	3	VCV	6	35%	0.4	8	0.30	281	F, M	− 5
9	3	PCV	NA	NA	NA	8	0.50	114	F, M, D	+ 1
10	2	PCV	5	30%	0.8	15	0.50	187	F, P	− 4
11	3	PCV	NA	NA	NA	8	0.30	213	P	− 3
12	3	VCV	5	30%	0.6	10	0.30	240	F	− 2
13	3	PCV	7	30%	0.3	10	0.35	193	F, M	− 4
14	3	PCV	6	30%	0.5	10	0.30	280	D	− 1
15	2	VCV	8	30%	2.0	10	0.50	137	F, P, M	− 3
16	4	PCV	12	15%	2.2	10	0.45	170	None	− 3
17	2	VCV	7	30%	0.5	8	0.40	215	F, M	− 4
18	4	VCV	10	30%	0.8	12	1.00	133	F	0
19	5	PCV	NA	NA	NA	13	1.00	314	F, P	− 4
20	4	VCV	NA	NA	NA	10	0.45	149	F, M	− 3

ID patient identification, MV_days days of mechanical ventilation before inclusion on the study, PS pressure support, Cycl_off cycling off in pressure support mode, NAVA_L level of neurally adjusted ventilatory assist (NAVA) during ventilation with NAVA mode, PEEP positive pressure at the end of expiration, FIO₂ fraction of inspired oxygen, P/F ratio of arterial oxygen pressure divided by the fraction of inspired oxygen on the day of the study, F continuous fentanyl, P continuous propofol, M continuous midazolam, D continuous dexmedetomidine, RASS Richmond Agitation–Sedation Scale at the day of study, NA not applicable